Ivermectin Dosing for Anti-Cancer Effects

Dose Considerations and Clinical Context

The standard clinical dose of ivermectin for approved parasitic infections is 200 μg/kg orally, which is significantly lower than concentrations needed for anti-cancer effects, as recommended by the Centers for Disease Control and Prevention 1, 2, 3
The therapeutic dose of ivermectin for scabies treatment is 200 μg/kg orally, repeated in 2 weeks, which is well below the concentrations used in cancer research, according to the Centers for Disease Control and Prevention 1, 2
For severe cases of crusted scabies, higher frequency dosing is used, but still at the same 200 μg/kg concentration, as per the Centers for Disease Control and Prevention 4, 5
The safety of multiple doses of ivermectin in patients with severe liver disease is not well established, which could be a concern for cancer patients with hepatic involvement, as noted by the Centers for Disease Control and Prevention 1, 6

Current medical guidelines do not support the use of ivermectin for cancer treatment, and the Infectious Diseases Society of America specifically recommends against ivermectin use even for COVID-19 treatment due to insufficient evidence of benefit, as stated by the Infectious Diseases Society of America 7, 8, 9

The safety profile of ivermectin at doses that might achieve anti-cancer effects has not been established, according to Praxis Medical Insights 6

The Infectious Diseases Society of America recommends against ivermectin use for COVID-19 treatment due to insufficient evidence of benefit, highlighting the pattern of inadequate clinical evidence for off-label uses, including cancer treatment 10

The World Health Organization has raised concerns that using ivermectin for diseases like COVID-19 risks diverting attention and resources away from evidence-based treatments, a pattern that may also apply to cancer treatment 11